ALL
Conference Coverage
CAR T cells produce complete responses in T-cell malignancies
ORLANDO – There were no cases of severe cytokine release syndrome or severe neurotoxicity reported with the anti-CD5 chimeric antigen receptor T...
Conference Coverage
Blinatumomab instead of chemo in young patients with relapsed ALL
ORLANDO – The “practice-changing” study found that blinatumomab was less toxic and allowed more patients to proceed to transplant.
Conference Coverage
ASH preview: Key themes include tackling CAR T obstacles, sickle cell advances, VTE
New findings take aim at CAR T-cell therapy-related obstacles and highlight potential new paths forward.
From the Journals
CAR T-cell ‘cocktail’ may overcome antigen escape relapse
The pilot study used a sequential infusion of a third-generation chimeric antigen receptor T-cell “cocktail” targeting CD19 and CD22.
Latest News
Researchers seek a way to predict cognitive deficits in children treated for ALL
Researchers are investigating gene variants and biomarkers that might correlate with chemotherapy-induced cognitive deficits.
From the Journals
Exercise intolerance linked to neurocognitive dysfunction in ALL
More study is needed to determine whether increasing exercise capacity would improve neurocognitive outcomes for childhood survivors of acute...
Conference Coverage
Immunotherapies under investigation in newly diagnosed B-ALL
SAN FRANCISCO – Researchers are testing blinatumomab and inotuzumab ozogamicin as first-line treatment in B-cell acute lymphoblastic leukemia.
From the Journals
Anakinra treatment for pediatric ‘cytokine storms’: Does one size fit all?
A retrospective cohort study saw mortality reduced if anakinra was administered early to treat sHLH/MAS. But experts caution that anakinra may not...
From the Journals
Stem cells gene edited to be HIV resistant treat ALL, but not HIV
Opinion
Predicting outcomes in acute leukemia, NSCLC
Dr. Alan Lyss examines the latest research on predicting VTE risk in patients with acute leukemia and new data on the impact of steroids in non–...
From the Journals
‘Robust antitumor immune responses’ observed in pediatric ALL
Tumor-associated CD8+ T cells responded to 86% of neoantigens tested and recognized 68% of neoepitopes tested in samples from pediatric ALL...